Christopher Ryan Sullivan - 28 Jan 2025 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVTX	Stock Option (Right to Buy)	Award	$0	+163,000		$0.000000	163,000	28 Jan 2025	Common Stock	163,000	$8.04	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.